Pieris Pharmaceuticals Inc  

(Public, NASDAQ:PIRS)   Watch this stock  
Find more results for PIRS
8.83
+0.20 (2.32%)
Real-time:   10:57AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.55 - 9.02
52 week 1.88 - 9.75
Open 8.61
Vol / Avg. 298,725.00/919,978.00
Mkt cap 395.53M
P/E     -
Div/yield     -
EPS -0.73
Shares 50.20M
Beta -78.08
Inst. own 48%
Feb 22, 2018
Pieris Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference - 3:35PM EST - Add to calendar
Feb 15, 2018
Pieris Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -179.74% -391.02%
Operating margin -132.01% -390.33%
EBITD margin - -383.47%
Return on average assets -27.65% -66.07%
Return on average equity -407.61% -80.91%
Employees 49 -
CDP Score - -

Address

255 State St Fl 9
BOSTON, MA 02109-2615
United States - Map
+1-857-2468998 (Phone)
+49-8161-1411444 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Officers and directors

James A. Geraghty Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Stephen S. Yoder President, Chief Executive Officer, Director
Age: 39
Bio & Compensation  - Reuters
Lance E. Thibault Acting Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Claude Knopf Senior Vice President, Chief Business Officer
Bio & Compensation  - Reuters
Louis A. Matis M.D. Senior Vice President and Chief Development Officer
Age: 54
Bio & Compensation  - Reuters
Julian Adams Director
Age: 61
Bio & Compensation  - Reuters
Jean-Pierre Bizzari M.D. Director
Age: 62
Bio & Compensation  - Reuters
Christopher P. Kiritsy Director
Age: 49
Bio & Compensation  - Reuters
Steven Prelack Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael Richman Independent Director
Age: 54
Bio & Compensation  - Reuters